Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Igh-6-Cd80)1Gjf mutation
(1 available)
|
|
|
hematopoietic system
|
N |
• there is no significant difference in lymphoid organ cellularity compare to Cd86 transgenic mice
|
|
|
• CD4/CD8 ratios in the thymus and spleen are significantly lower than those of control littermates
|
immune system
|
|
• CD4/CD8 ratios in the thymus and spleen are significantly lower than those of control littermates
|
Allelic
Composition |
Tg(Igh-6-Cd80)1Gjf/0
|
|
Genetic
Background |
involves: BALB/c * C57BL/6 * CBA |
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Igh-6-Cd80)1Gjf mutation
(1 available)
|
|
|
hematopoietic system
|
N |
• there is no significant difference in lymphoid organ cellularity compare to Cd86 transgenic mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Igh-6-Cd80)1Gjf mutation
(1 available)
|
|
|
immune system
|
|
• a defect in B cell maturation similar to that in Tg(Igh-6-Cd80)1Gjf mice is observed
• 3 week old transgenics have fewer B cells than wild-type mice; percentage of B cells in the spleens of young wild-type is 54% vs 25% in transgenics
• adult mice have comparable numbers of B cells in the spleens to wild-type
|
|
|
• transgene expressing T cells can be activated by anti-CD3 alone, whereas wild-type T cells require presence of costimulatory signals for activation
|
|
|
• T cells stimulated with wild-type B cells show poor activation in contrast to cells stimulated with B cells expressing the transgene
|
|
|
• in response to TNP-KLH, T cell responses are normal but B cell antibody responses are reduced
• when mice are treated with anti-Cd80, capacity to produce antibodies in response to hapten-protein conjugates is restored
|
|
|
• all Ig isotypes are reduced in transgenic mice in response to TNP-KLH; the same defect is seen with another hapten conjugate TNP-ovalbumin
|
hematopoietic system
|
|
• a defect in B cell maturation similar to that in Tg(Igh-6-Cd80)1Gjf mice is observed
• 3 week old transgenics have fewer B cells than wild-type mice; percentage of B cells in the spleens of young wild-type is 54% vs 25% in transgenics
• adult mice have comparable numbers of B cells in the spleens to wild-type
|
|
|
• all Ig isotypes are reduced in transgenic mice in response to TNP-KLH; the same defect is seen with another hapten conjugate TNP-ovalbumin
|
|
|
• transgene expressing T cells can be activated by anti-CD3 alone, whereas wild-type T cells require presence of costimulatory signals for activation
|
|
|
• T cells stimulated with wild-type B cells show poor activation in contrast to cells stimulated with B cells expressing the transgene
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Igh-6-Cd80)1Gjf mutation
(1 available)
|
|
|
immune system
|
|
• mononuclear infiltration is present, but reduced, in pancreatic islets as compared to control
|
|
|
• Background Sensitivity: reduction in percentage of circulating B cells beginning at 2 weeks of age
• treatment with anti-Cd8 mAb beginning at 3 weeks of age results in an increase in the percentage of B cells to almost control levels
• B cells represent 2-3% of cells in blood in contrast to 20-30% found in NOD controls
• 2 - 2.5 fold reduction of splenic B cells as compared to NOD controls
• immature/mature (B220+, IgM+) B cells reduced more than 10 fold in bone marrow
|
|
|
• immature/mature (B220+, IgM+) B cells are reduced more than 10 fold in bone marrow
|
|
|
• percentage of B-2 B cells is decreased greater than 5 fold in the peritoneal cavity, however, numbers of B-1 B cells are not significantly changed
|
|
|
• severe depletion of mature (CD2 1ow IgM low) follicular B cells in spleen, however, marginal zone B cells are mostly unaffected
|
|
|
• splenic transgenic B cells proliferate in cell transfer experiments
|
|
|
• circulating IgM, IgG2b, IgG3 and IgG1 levels reduced
• treatment with anti-Cd8 mAb beginning at 3 weeks of age results in an increase in circulating immunoglobulin levels
|
|
|
• CD8+ T cell depletion leads to restoration of B cell numbers
|
|
|
• class II expression is increased by 2 fold in splenic B cells
|
|
|
• transgenic mice do not develop diabetes
|
hematopoietic system
|
|
• decrease in number of B cells in bone marrow
• pre/pro (B220+, IgM-) B cells are reduced less than 2 fold
• immature/mature (B220+, IgM+) B cells are reduced more than 10 fold
|
|
|
• Background Sensitivity: reduction in percentage of circulating B cells beginning at 2 weeks of age
• treatment with anti-Cd8 mAb beginning at 3 weeks of age results in an increase in the percentage of B cells to almost control levels
• B cells represent 2-3% of cells in blood in contrast to 20-30% found in NOD controls
• 2 - 2.5 fold reduction of splenic B cells as compared to NOD controls
• immature/mature (B220+, IgM+) B cells reduced more than 10 fold in bone marrow
|
|
|
• immature/mature (B220+, IgM+) B cells are reduced more than 10 fold in bone marrow
|
|
|
• percentage of B-2 B cells is decreased greater than 5 fold in the peritoneal cavity, however, numbers of B-1 B cells are not significantly changed
|
|
|
• severe depletion of mature (CD2 1ow IgM low) follicular B cells in spleen, however, marginal zone B cells are mostly unaffected
|
|
|
• splenic transgenic B cells proliferate in cell transfer experiments
|
|
|
• circulating IgM, IgG2b, IgG3 and IgG1 levels reduced
• treatment with anti-Cd8 mAb beginning at 3 weeks of age results in an increase in circulating immunoglobulin levels
|
|
|
• CD8+ T cell depletion leads to restoration of B cell numbers
|
endocrine/exocrine glands
|
|
• mononuclear infiltration is present, but reduced, in pancreatic islets as compared to control
|
Analysis Tools